Exposure to certain man-made and natural environmental agents poses a significant threat to human health. In order to enable us to establish rational policies to deal with this health issue, we need to expand our knowledge about the mechanisms by which toxic and carcinogenic environmental agents compromise human health. Toxicity and cancer caused by the nongenotoxic agent 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) and the ubiquitous environmental combustion product benzo[a]pyrene (BaP) appear to be mediated by way of the aromatic hydrocarbon receptor (AHR). Previous work from this and other laboratories has shown that (a) there exist inbred mouse strains having genes for high- and low-affinity AHRs;(b) mice with the high-affinity-AHR phenotype metabolize numerous environmental chemicals, to form reactive intermediates, 15-20 times faster than mice with the low-affinity-AHR phenotype; (c) DNA adduct formation, mutagenesis, oncogene activation, and certain types of cancer occur more frequently in mice with the fast- metabolism phenotype; and (d) approximately one-tenth of the human population has a fast-metabolism phenotype, and in this group the risk of certain types of cancer among smokers appears to be several-fold greater than that in the slow-metabolism group. The laboratory animal data for high vs low-affinity-AHR differences in toxicity and cancer are very convincing, whereas the human AHR-related differences in toxicity and cancer remain equivocal, largely due to the ethical difficulties in carrying out definitive experiments in humans. Here we propose to: (1) determine the nucleotide difference(s) in the human AHR gene responsible for human high and low-affinity-AHR phenotype among members in one 3- generation family; (2) make heterozygous and homozygous disruptions of the Ahr gene in murine embryonic stem (ES) cells; (3) replace the murine disrupted gene with the human low-affinity (AHR) gene in one cell line, and in another cell line with the human high-affinity (AHRA) gene; and (4) generate the two human transgenic mouse lines. These animals will be helpful in examining the role of the human high vs low-affinity AHR in toxicity and cancer-- on a common mouse background where every other gene is identical. This project goes substantially beyond what we and others have already done in this field. These mice will be invaluable for defining the precise role of the human Ah receptor in innumerable studies of toxicity and cancer caused by TCDD, BaP and other environmental chemicals. These mice should become important, valid dose- response models needed for a rational approach to human risk assessment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
1R01ES006811-01
Application #
2155710
Study Section
Toxicology Subcommittee 2 (TOX)
Project Start
1994-06-01
Project End
1997-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Shertzer, H G; Puga, A; Chang, C et al. (1999) Inhibition of CYP1A1 enzyme activity in mouse hepatoma cell culture by soybean isoflavones. Chem Biol Interact 123:31-49
Maier, A; Micka, J; Miller, K et al. (1998) Aromatic hydrocarbon receptor polymorphism: development of new methods to correlate genotype with phenotype. Environ Health Perspect 106:421-6
Fitzgerald, C T; Nebert, D W; Puga, A (1998) Regulation of mouse Ah receptor (Ahr) gene basal expression by members of the Sp family of transcription factors. DNA Cell Biol 17:811-22
DiRocco, L; Dalton, T; Liang, D et al. (1998) Nonallelism for the audiogenic seizure prone (Asp1) and the aryl hydrocarbon receptor (Ahr) loci in mice. J Neurogenet 12:191-203
Micka, J; Milatovich, A; Menon, A et al. (1997) Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 7:95-101
He, X X; Nebert, D W; Vasiliou, V et al. (1997) Genetic differences in alcohol drinking preference between inbred strains of mice. Pharmacogenetics 7:223-33
Nebert, D W (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265-71
Nebert, D W; Duffy, J J (1997) How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem Pharmacol 53:249-54
Nebert, D W; Carvan 3rd, M J (1997) Ecogenetics: from ecology to health. Toxicol Ind Health 13:163-92
Nebert, D W; McKinnon, R A; Puga, A (1996) Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-80

Showing the most recent 10 out of 14 publications